Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Moreno

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
BMJ Open|May 30, 2025
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre studyVivian D de Jong, Marco Alings, Radan Bruha, et al.
Journal of Hepatology|June 14, 2021
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver diseaseCarolin Lackner, Rudolf E Stauber, Susan Davies, et al.
JHEP Reports : Innovation in Hepatology|February 27, 2023
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver diseaseAndré Lopes Simão, Carolina Santos Palma, Laura Izquierdo-Sanchez, et al.
Alimentary Pharmacology & Therapeutics|November 20, 2025
Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue CessationArno Furquim d'Almeida, Axelle Vanderlinden, Stefan Bourgeois, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Journal of Hepatology|June 6, 2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT studyAudrey Coilly, Claire Fougerou-Leurent, Victor de Ledinghen, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2019
Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial PeritonitisJavier Fernández, Paolo Angeli, Jonel Trebicka, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
BMJ Open|May 30, 2025
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre studyVivian D de Jong, Marco Alings, Radan Bruha, et al.
Journal of Hepatology|June 14, 2021
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver diseaseCarolin Lackner, Rudolf E Stauber, Susan Davies, et al.
JHEP Reports : Innovation in Hepatology|February 27, 2023
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver diseaseAndré Lopes Simão, Carolina Santos Palma, Laura Izquierdo-Sanchez, et al.
Alimentary Pharmacology & Therapeutics|November 20, 2025
Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue CessationArno Furquim d'Almeida, Axelle Vanderlinden, Stefan Bourgeois, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Journal of Hepatology|June 6, 2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT studyAudrey Coilly, Claire Fougerou-Leurent, Victor de Ledinghen, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2019
Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial PeritonitisJavier Fernández, Paolo Angeli, Jonel Trebicka, et al.
Pageof 17